This finding was consistent with that in a study by Shien et al. in which three lung cancer cell lines with EGFR mutations became gefitinib-resistant with different mechanisms after stepwise escalation of chronic exposure to gefitinib [25]. The gene discussed is EGFR; the disease is lung carcinoma.